News >

Expert Explains Evolution of De-Escalating Therapies in HER2+ Breast Cancer

Ellie Leick
Published: Friday, Jul 19, 2019

Keerthi Gogineni, MD, MSHP, assistant professor in the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute

Keerthi Gogineni, MD, MSHP

Several trials, such as APT and KRISTINE, have examined the effects of de-escalating treatment for patients with HER2-positive breast cancer in an effort to decrease toxicity without comprising efficacy, explained Keerthi Gogineni, MD, MSHP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x